<prompt> Dose dependant least neurotoxicity is found inCisplatinBleomycinDoxorubicinVinblastin  <response>: i.e. Bleomycin: 527-H17thDOXORUBICIN 525-H17th Predictable myelosuppression Alopecia, nausea, mucositis Cardiotoxicy in the form of atrial and ventricular dysarrhythmias Powerful vesicant with necrosis of tissue apparent 4-7 days after an extravasation Dexrazoxane is an antidote to doxorubicin-induced extravasationBLEOMYCIN Antibiotics 525-H17th Fever and chills, facial flush, and Raynauds phenomenon Hypertension, anaphylaxis Pulmonary fibrosis Little myelosuppressionCISPLATIN - 524-H17th Renal impairment is common Hypomagnesemia, hypocalcemia and tetany Neurotoxicity with stocking and glove sensory motor neuropathy Hearing loss 50 Highly emetic drugs Myelosuppression is less Chronic vascular toxicity Raynauds phenomenon, Coronary artery disease is a more unusual toxicity Cisplatin is accumulated by proximal tubular cells where it induces mitochondrial injury and causes apoptosis and necrosis of renal tubular cells - ARF Cisplatin is mutagenic, teratogenic and carcinogenic - Secondary leukemias are reported with the use of cisplatin and the use of cisplatin or carbolatin based chemotherapy for women with ovarian cancer is associated with a fourfold increased risks of developing secondary leukemia 1433-Goodman Gilman 10th Cisplatin has been associated with the development of AML usually 4 years or more after treatment -Lawrence 